Latest news

• Novartis’ Promacta receives US breakthrough therapy designation

  The news comes hot on the heels of FDA breakthrough status for the company’s breast cancer drug Kisqali.

• Novartis bags new breakthrough status for Kisqali in breast cancer

  Novartis bags new breakthrough status for Kisqali in breast cancer. The Swiss pharma group’s treatment will rival Lilly’s Verzenio and Pfizer’s Ibrance if approved. ... EvaluatePharma recently predicted that Ibrance will become a mega-blockbuster

• NICE backs two advanced breast cancer drugs after price cuts

  NICE has recommended that Kisqali can be used in post-menopausal patients, while Ibrance can be used in this group as well as younger women. ... Kisqali has a lot of ground to catch up but is still expected to be a big seller, reaching $1.6bn in sales in

• Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

  Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone. ... New phase III data for Novartis’CDK4/6 inhibitor Kisqali has shown that the drug is effective in tackling breast cancer in younger women.

• Prospects for Lilly’s Verzenio hit by botched lung cancer trial

  palbociclib) and Novartis with recently-launched Kisqali (ribociclib), although it reckons Verzenio can still lead in breast cancer after picking up an early approval from the FDA towards the end of ... Neither Ibrance nor Kisqali are in large-scale